Pediatric Lupus Biomarker Study, Canada

Registration Status: Completed

Objective: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect any organ of the body. Of all cases, 15% present with onset during childhood, and 30-50% involve the kidneys (typically lupus nephritis). It is unknown why some SLE patients present with lupus nephritis and other do not. It is also unknown whether the natural history and therapeutic responses of patients with lupus nephritis differ when onset is during childhood as opposed to onset as an adult. The biospecimens collected in the Pediatric Lupus Biomarker Study will be used to address three specific aims: (1) Identify diagnostic biomarkers that can predict kidney involvement in childhood-onset SLE, (2) Identify predictive biomarkers that can determine responses to targeted disease therapies, (3) Identify predictive biomarkers that can determine impending lupus nephritis flare? To these aims, PBMC, plasma, urine, and saliva have been collected from patients with SLE at several pediatric sites thru the Pediatric Nephrology Research Consortium. Originally stored at Baylor College of Medicine and Texas Children's Hospital in Houston, TX, USA, this biobank was relocated to Vancouver in 2022 when Scott Wenderfer accepted a position with PHSA at BC Children's Hospital and became a Clinical Professor in the Faculty of Medicine at the University of British Columbia. A material transfer agreement was executed between BCM, PHSA, and UBC to maintain the biobank in Vancouver for the purpose of collaborative research addressing these three specific aims.

Registered Biobank Name	Pediatric Lupus Biomarker Study
Biobank Leader	Scott Wenderfer
Country	Canada
Email for biobank inquiries	scott.wenderfer@cw.bc.ca
Principal Investigator	Scott Wenderfer
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).